Full-Time

Principal Scientist

Translational Sciences

Posted on 5/16/2024

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

Biotechnology
Healthcare

Compensation Overview

$160k - $175kAnnually

+ Bonus + Equity Grant

Senior, Expert

North Bethesda, MD, USA

Relocation assistance is offered if required.

Category
Genomics
Biology Lab & Research
Biology & Biotech

You match the following Arcellx's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • PhD, MD or MD/PhD degree in a relevant scientific field (e.g., cancer biology, immunology, hematology)
  • 8+ years post-degree experience, inclusive of 3+ years of experience in a formalized Translational Science/Medicine role within a large pharma/biotech company
  • Understanding of early or late-stage drug and translational development process, including clinical trial experience in industry or academia
  • In-depth understanding of myeloid disease biology (e.g., AML, MDS)
  • Demonstrated record of research accomplishment as evidenced by publications or major contributions to drug development milestones
  • Highly developed problem solving and risk management abilities
  • Strategic thinker with proven leadership skills and/or prior project team leadership roles
  • Proficiency in distilling complex issues and clearly articulating viable paths forward
Responsibilities
  • Lead implementation of clinical biomarker strategy to enable target engagement characterization, PK/PD indication of biologic activity and assessment of patient response
  • Serve as a key contributor to integrate, influence, and execute on translational/biomarker plans
  • Communicate translational updates and conduct strategic discussions for key programs with diverse audiences, including senior management
  • Understand key cancer pathway interactions and feedback mechanisms in clinical samples to inform ongoing clinical trials
  • Define novel mechanisms of resistance by studying samples at relapse
  • Contribute relevant scientific expertise, strategy, and experimentally-derived insights as a member of multidisciplinary project teams working to drive the preclinical to clinical translation of pipeline assets
  • Plan, design, and execute IND-enabling pharmacology, pharmacokinetic and toxicology studies by applying knowledge of disease-associated pathways, preclinical models, and drug development
  • Contribute to the preparation of IND applications and other regulatory documents, as appropriate, leveraging up-to-date knowledge of FDA cellular therapy guidance
  • Establish and cultivate relationships with external CRO collaborators for basic and translational research
  • Maintain a current and comprehensive understanding of disease biology, treatment paradigm, and competitive landscape for key programs

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary immunotherapy products and has a business model that includes research, development, and commercialization, generating revenue through partnerships and licensing agreements. The main goal of Arcellx is to meet unmet medical needs by creating safe and effective treatment options.

Company Stage

IPO

Total Funding

$194.5M

Headquarters

Gaithersburg, Maryland

Founded

2014

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

2%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic partnership with Kite accelerates development and commercialization of therapies.
  • FDA support expedites approval process for Arcellx's innovative treatments.
  • Advancements in gene editing enhance precision of Arcellx's cell therapies.

What critics are saying

  • Competition from established CAR-T therapies like Abecma and Carvykti.
  • Dependency on Kite partnership could pose risks if dynamics change.
  • Phase 3 trial for anito-cel carries risk of not meeting endpoints.

What makes Arcellx unique

  • Arcellx's CART-ddBCMA has FDA Fast Track, Orphan Drug, and RMAT designations.
  • The ARC-SparX platform offers dosable and controllable CAR-T therapy options.
  • Anito-cel uses a novel D-Domain BCMA binder for enhanced antigen binding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

INACTIVE